RT @Sandra_Cab5: ESRD pts with VTE no longer require admission for heparin bridge. If stable, these pt’s can be discharged on apixaban with…
ESRD pts with VTE no longer require admission for heparin bridge. If stable, these pt’s can be discharged on apixaban with follow up. Additionally, apixaban found to have significantly lower recurrence of VTE when compared to warfarin. #CincyAI https://t.c
FMI Apixaban has already approved in USA on 2018, but not in Japan. Even apixaban may be safer and less risky for patients with dialysis, there is solely a choice of warfarin in Japan. Further research and approval from the health ministry are needed.
@AVD_PharmD19 As far as powering for PK goes I'm with you there. Unfortunately only 11 patients on apixaban for NVAF were included so true comparison to warfarin for AFib is still pretty cloudy and a great opportunity for future research imo https://t.co/k